Enveric Biosciences (NASDAQ:ENVB) Trading Down 5.2%

Enveric Biosciences, Inc. (NASDAQ:ENVB – Get Rating)’s stock price traded down 5.2% during trading on Monday . The stock traded as low as $1.84 and last traded at $1.84. 7,305 shares changed hands during mid-day trading, a decline of 79% from the average session volume of 34,771 shares. The stock had previously closed at $1.94.

Enveric Biosciences Price Performance

The company has a market cap of $3.83 million, a PE ratio of -0.02 and a beta of 1.51. The stock has a fifty day moving average price of $2.53 and a 200-day moving average price of $3.45.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ENVB. UBS Group AG boosted its holdings in Enveric Biosciences by 601.0% during the first quarter. UBS Group AG now owns 97,904 shares of the company’s stock valued at $32,000 after acquiring an additional 83,938 shares during the period. Millennium Management LLC bought a new stake in Enveric Biosciences during the second quarter worth about $49,000. Virtu Financial LLC grew its position in Enveric Biosciences by 96.3% during the 1st quarter. Virtu Financial LLC now owns 276,184 shares of the company’s stock worth $91,000 after acquiring an additional 135,474 shares during the last quarter. AdvisorShares Investments LLC increased its stake in shares of Enveric Biosciences by 35.8% in the second quarter. AdvisorShares Investments LLC now owns 1,252,390 shares of the company’s stock valued at $268,000 after buying an additional 330,019 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in Enveric Biosciences by 259.2% in the 1st quarter. Renaissance Technologies LLC now owns 1,990,600 shares of the company’s stock valued at $657,000 after acquiring an additional 1,436,500 shares in the last quarter. Institutional investors and hedge funds own 13.40% of the company’s stock.

Enveric Biosciences Company Profile

(Get Rating)

Enveric Biosciences, Inc develops cannabinoid medicines and combination therapies. It is a patient-centric biotechnology company endeavouring to enhance the lives of those who are adversely affected by the side effects of Cancer Treatments. The firm is testing natural compounds, starting with cannabinoids to provide patients and clinicians with novel prescription medicines to serve these unmet medical needs.